Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Ultra‐Large Virtual Screening: Definition, Recent Advances, and Challenges in Drug Design

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery

Advances in machine intelligence-driven virtual screening approaches for big-data

Structure-Based Virtual Screening: Successes and Pitfalls

Deep Learning in Virtual Screening: Recent Applications and Developments

Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking

Molecular docking-based computational platform for high-throughput virtual screening

Virtual Screening Methods As Tools for Drug Lead Discovery from Large Chemical Libraries.

Virtual Screening Methods As Tools For Drug Lead Discovery From Large Chemical Libraries

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

Recent Developments in Structure-Based Virtual Screening Approaches

Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances

Combined Usage of Ligand- and Structure-based Virtual Screening in the Artificial Intelligence Era

An artificial intelligence accelerated virtual screening platform for drug discovery

Recent Development and Application of Virtual Screening in Drug Discovery: An Overview

Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Merging Ligand-Based and Structure-Based Methods in Drug Discovery: An Overview of Combined Virtual Screening Approaches

Multiple-step Virtual Screening Using VSM-G: Overview and Validation of Fast Geometrical Matching Enrichment